Thu, Dec 18, 2014, 11:01 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • slumdawg2011 slumdawg2011 Dec 17, 2012 1:24 AM Flag

    Ariad and Medivation drugs

    were approved 3 months ahead of PDUFA dates. What's taking the FDA too long to approved T-DM1 with its trial numbers? I guess there is a fair chance that approval will be announced last week of Dec. Ho-ho-ho! Should I be adding Jan calls, or will I lose money on those again? No-no-no!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • lately, biotech stocks that run up in advance of FDA are being sold on the approval news. IMGN has not exactly run up, but has moved up some from being massively oversold. I would not be surprised to see the immediate reaction as a sell, or if there is a sharp move up, shorts will sell hard into it then covering/accumulation should start. Shorts have to show they are still in control and seem to have unlimited selling resources. Take a look at ARIA, $25 to $20 to $24 just before approval then sold off to $19 after the approval and is now in the covering/accumulation mode IMO, but I am not playing it. If you are buying calls, go in the money and give it some time. Premiums are low, so expectations are also low. It might take a few quarters of large sales data of some other clinical progress to change the expectations.

    • Celldex is a solid stock too imo.
      We expect that a study sponsored by the Cancer Immunotherapy Trials Network will be initiated in 2013.”

 
IMGN
10.85+0.12(+1.17%)Dec 18 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.